Laurus Labs to invest Rs 83 crore in KRKA Pharma
Hyderabad: Laurus Labs has announced that the Company has approved an investment of Rs 83 crore in KRKA Pharma, a joint venture of the Company.
KRKA Pharma is already a joint venture company of the Company and further investment by the Company and by KRKA d.d., Novo mesto, Slovenia (“co-venturer”) will enable KRKA to acquire land and to meet initial cost of setting up of a manufacturing facility.
The investment by the Company is expected to be completed on or before 31.03.2025.
Read also: Submit additional data: CDSCO Tells Laurus Labs to on Carglumic acid dispersible tablets
KRKA Pharma Private Limited, a joint venture of the Company, incorporated under the Companies Act, 2013. The Authorised Share Capital of KRKA is Rs 2700,000,000/- divided into 270,000,000 equity shares of Rs 10/- each and paid-up Share Capital of the Company is Rs 450,000,000/- divided into 45,000,000 equity shares of Rs 10/- each.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.